Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.
The partnership will see the Oxford, England-based biotech company provide the UK’s largest independent charitable hospital with cancer detecting EpiSwitch blood testing products.
This agreement covers both the prostate screening and checkpoint inhibitor response tests.
Chief Executive Officer Jon Burrows said: ‘Through this new partnership with The London Clinic we are delivering potentially life-changing blood tests, which can safeguard the wellbeing of at-risk patients whilst reducing the cost of care.’
This latest announcement follows October’s deal with Bupa UK to provide coverage for the EpiSwitch CiRT test.
Oxford BioDynamics shares were up 4.2% to 7.92 pence each in London on Tuesday afternoon.
Copyright 2024 Alliance News Ltd. All Rights Reserved.